Published May 17, 2021, 3:30 PM
As the lead agency for health and health-related research initiatives, Department of Science and Technology – Philippine Council for Health Research and Development (DOST-PCHRD) continues to support various health research projects and activities to help address the challenges brought by the coronavirus disease (COVID-19) pandemic in the country.
The DOST-PCHRD presented several health research projects and innovations related to COVID-19 during the “Talakayang HeaRTBeat” on May 17, 2021. (Screengrab from DOST PCHRD Facebook page)
During the virtual “Talakayang HeaRTBeat” on Monday, May 17, the DOST-PCHRD presented several health research projects and innovations that have already provided significant inputs and contributions in the field of diagnostics, public health surveillance, and treatment for COVID-19.
Over 40 Filipinos have undergone the clinical trial on the efficacy and safety of convalescent plasma transfusion as adjunctive therapy to prevent disease progression among hospitalized coronavirus disease (COVID-19) patients, the Department of Science and Technology (DOST) has reported.
(Photo b
By HANA BORDEY, GMA News
Published May 7, 2021 12:56pm The Philippine Red Cross is open to conduct clinical trials in its isolation facilities as long as the government will facilitate the procedures, Senator Richard Gordon said Friday. “Basta papayag ang mga pasyente, wala pa naman akong nalalaman na namatay sa ivermectin, basta papayag sila at ang gobyerno natin ang mangangasiwa,” Gordon said during the Laging Handa briefing. (We are open to this as long as the patient will give their consent and as long as the government will conduct it.) He was reacting to Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) executive director Dr. Jaime C. Montoya’s statement that the government is eyeing the use of PRC facilities as sites for the clinical trial and their patients can participate voluntarily in the study.
Philippine Red Cross Isolation Facility (Photo from PRC)
This was bared by Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) Executive Director Dr. Jaime C. Montoya during a televised public briefing on Monday, May 3.
“Tinitingnan na po natin ngayon ay mga quarantine facilities ng Philippine Red Cross, kasama po natin sila sa pagaaral na isasagawa (We are looking at the quarantine facilities of the Philippine Red Cross, they are with us in the study that will be conducted),” he said.
He clarified that the participation of the coronavirus disease (COVID-19) patients with mild to moderate cases in the clinical trial is “voluntary”.
Published May 3, 2021, 12:22 PM
The Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) said on Monday, May 3, that the clinical trial on the use of Ivermectin as a treatment for coronavirus disease (COVID-19) will involve patients with “non-severe” or those with mild to moderate cases.
DOST-PCHRD Executive Director Dr. Jaime C. Montoya (Manila Bulletin File Photo)
DOST-PCHRD Executive Director Dr. Jaime C. Montoya said the research team from the University of the Philippines (UP) Manila- Philippine General Hospital (PGH), headed by Dr. Aileen Wang, is now drafting the research protocol, which includes the timeline of the clinical trial and the target participants.